company background image


Last Price


Market Cap







29 Sep, 2022


Company Financials +
ERYP fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health5/6

ERYP Stock Overview

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States.

ERYTECH Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ERYTECH Pharma
Historical stock prices
Current Share Price€0.57
52 Week High€5.50
52 Week Low€0.54
1 Month Change-33.62%
3 Month Change-48.79%
1 Year Change-88.82%
3 Year Change-85.44%
5 Year Change-97.66%
Change since IPO-95.02%

Recent News & Updates

Shareholder Returns

ERYPFR BiotechsFR Market

Return vs Industry: ERYP underperformed the French Biotechs industry which returned -55.4% over the past year.

Return vs Market: ERYP underperformed the French Market which returned -12.7% over the past year.

Price Volatility

Is ERYP's price volatile compared to industry and market?
ERYP volatility
ERYP Average Weekly Movement8.7%
Biotechs Industry Average Movement7.3%
Market Average Movement4.9%
10% most volatile stocks in FR Market9.3%
10% least volatile stocks in FR Market2.8%

Stable Share Price: ERYP is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ERYP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

2004149Gil Beyen

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers.

ERYTECH Pharma Fundamentals Summary

How do ERYTECH Pharma's earnings and revenue compare to its market cap?
ERYP fundamental statistics
Market Cap€17.73m
Earnings (TTM)-€26.87m
Revenue (TTM)€2.86m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ERYP income statement (TTM)
Cost of Revenue€0
Gross Profit€2.86m
Other Expenses€29.73m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 08, 2022

Earnings per share (EPS)-0.87
Gross Margin100.00%
Net Profit Margin-938.49%
Debt/Equity Ratio82.6%

How did ERYP perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is ERYP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ERYP?

Other financial metrics that can be useful for relative valuation.

ERYP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does ERYP's PS Ratio compare to its peers?

ERYP PS Ratio vs Peers
The above table shows the PS ratio for ERYP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.4x
ADOC Adocia
LYS Lysogene
ALVET TheraVet

Price-To-Sales vs Peers: ERYP is expensive based on its Price-To-Sales Ratio (6.2x) compared to the peer average (4.4x).

Price to Earnings Ratio vs Industry

How does ERYP's PE Ratio compare vs other companies in the FR Biotechs Industry?

Price-To-Sales vs Industry: ERYP is expensive based on its Price-To-Sales Ratio (6.2x) compared to the French Biotechs industry average (6.1x)

Price to Sales Ratio vs Fair Ratio

What is ERYP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ERYP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.2x
Fair PS Ratio31.3x

Price-To-Sales vs Fair Ratio: ERYP is good value based on its Price-To-Sales Ratio (6.2x) compared to the estimated Fair Price-To-Sales Ratio (31.3x).

Share Price vs Fair Value

What is the Fair Price of ERYP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ERYP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ERYP's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is ERYTECH Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ERYP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ERYP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ERYP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ERYP's revenue (77.2% per year) is forecast to grow faster than the French market (5.3% per year).

High Growth Revenue: ERYP's revenue (77.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ERYP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has ERYTECH Pharma performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ERYP is currently unprofitable.

Growing Profit Margin: ERYP is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ERYP is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.

Accelerating Growth: Unable to compare ERYP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ERYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).

Return on Equity

High ROE: ERYP has a negative Return on Equity (-119.76%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is ERYTECH Pharma's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ERYP's short term assets (€62.1M) exceed its short term liabilities (€27.6M).

Long Term Liabilities: ERYP's short term assets (€62.1M) exceed its long term liabilities (€16.0M).

Debt to Equity History and Analysis

Debt Level: ERYP has more cash than its total debt.

Reducing Debt: ERYP's debt to equity ratio has increased from 3.5% to 82.6% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ERYP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ERYP has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 16.1% each year.

Discover healthy companies


What is ERYTECH Pharma current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

ERYTECH Pharma Dividend Yield vs Market
How does ERYTECH Pharma dividend yield compare to the market?
SegmentDividend Yield
Company (ERYTECH Pharma)n/a
Market Bottom 25% (FR)2.0%
Market Top 25% (FR)6.2%
Industry Average (Biotechs)2.2%
Analyst forecast in 3 Years (ERYTECH Pharma)n/a

Notable Dividend: Unable to evaluate ERYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ERYP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ERYP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ERYP's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ERYP has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Gil Beyen (60 yo)





Mr. Gil Beyen, BVBA has been the Chief Executive Officer of ERYTECH Pharma S.A. since May 2013. For more than ten years, Mr. Beyen has been a Management Consultant at Arthur D. Little in Brussels and serve...

CEO Compensation Analysis

Gil Beyen's Compensation vs ERYTECH Pharma Earnings
How has Gil Beyen's remuneration changed compared to ERYTECH Pharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021€751k€399k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020€957k€409k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019€791k€399k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018€657k€345k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017€645k€276k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016€611k€276k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015€414k€270k


Compensation vs Market: Gil's total compensation ($USD733.72K) is above average for companies of similar size in the French market ($USD342.35K).

Compensation vs Earnings: Gil's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: ERYP's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Experienced Board: ERYP's board of directors are seasoned and experienced ( 10 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ERYP?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders28,1270.09%
Private Companies431,0351.4%
Hedge Funds5,396,59717.4%
General Public19,836,83864.0%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.9%.

Top Shareholders

Top 25 shareholders own 36.48% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
BVF Partners L.P.
UBS Asset Management
1,986,669€1.1m0.44%no data
RA Capital Management, L.P.
Auriga Partners
Armistice Capital LLC
Recordati Orphan Drugs
431,034€246.3k0%no data
Goldman Sachs Group, Investment Banking and Securities Investments
188,991€108.0k0%no data
Aviva Investors Global Services Limited
168,861€96.5k0%no data
Vanguard Personalized Indexing Managment, LLC
95,268€54.4k0%no data
Citadel Advisors LLC
70,292€40.2k106.91%no data
La Française Systematic Asset Management GmbH
BBVA Asset Management, S.A., S.G.I.I.C.
25,000€14.3k0%no data
Etoile Gestion
18,447€10.5k0%no data
Group One Trading LP, Asset Management Arm
10,590€6.1k1.68%no data
Philippe Archinard
10,300€5.9k0%no data
Deka Investment GmbH
8,700€5.0k0%no data
Eric Soyer
6,264€3.6k0%no data
Gil Beyen
4,840€2.8k0%no data
Credit Suisse, Investment Banking and Securities Investments
4,229€2.4k0%no data
Jérôme Bailly
3,798€2.2k0%no data
Geode Capital Management, LLC
2,542€1.5k2.33%no data
Brian Schwab
1,279€730.90%no data
Anne-Cécile Fumey
864€493.80%no data
Françoise Horand-Phothirath
780€445.80%no data

Company Information

ERYTECH Pharma S.A.'s employee growth, exchange listings and data sources

Key Information

  • Name: ERYTECH Pharma S.A.
  • Ticker: ERYP
  • Exchange: ENXTPA
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €17.726m
  • Shares outstanding: 31.02m
  • Website:

Number of Employees


  • ERYTECH Pharma S.A.
  • 60 Avenue Rockefeller
  • Lyon
  • Rhône-Alpes
  • 69008
  • France


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ERYPENXTPA (Euronext Paris)YesCategory O SharesFREURApr 2013
ERYPPBATS-CHIXE (BATS 'Chi-X Europe')YesCategory O SharesGBEURApr 2013
0QSSLSE (London Stock Exchange)YesCategory O SharesGBEURApr 2013
20000DB (Deutsche Boerse AG)YesCategory O SharesDEEURApr 2013
ERYPNasdaqGS (Nasdaq Global Select)SPON ADR EACH REPR 1 ORDUSUSDMar 2015
2E4ADB (Deutsche Boerse AG)SPON ADR EACH REPR 1 ORDDEEURMar 2015

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.